Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly...
Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas
About this item
Full title
Author / Creator
Raj, Nitya , Chan, Jennifer A. , Wang, Stephanie J. , Aggarwal, Rahul R. , Calabrese, Susan , DeMore, April , Fong, Lawrence , Grabowsky, Jennifer , Hope, Thomas A. , Kolli, Kanti Pallav , Mulvey, Claire K. , Munster, Pamela N. , Perez, Kimberly , Punn, Sippy , Reidy-Lagunes, Diane , Von Fedak, Sofia , Zhang, Li and Bergsland, Emily K.
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Background
To date, single-agent immune checkpoint inhibitor (CPI) therapy has proven to be ineffective against biomarker-unselected extrapulmonary poorly differentiated neuroendocrine carcinomas (EP-PDNECs). The efficacy of CPI in combination with chemotherapy remains under investigation.
Methods
Patients with advanced, progressive EP-PDN...
Alternative Titles
Full title
Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas
Authors, Artists and Contributors
Author / Creator
Chan, Jennifer A.
Wang, Stephanie J.
Aggarwal, Rahul R.
Calabrese, Susan
DeMore, April
Fong, Lawrence
Grabowsky, Jennifer
Hope, Thomas A.
Kolli, Kanti Pallav
Mulvey, Claire K.
Munster, Pamela N.
Perez, Kimberly
Punn, Sippy
Reidy-Lagunes, Diane
Von Fedak, Sofia
Zhang, Li
Bergsland, Emily K.
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10338510
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10338510
Other Identifiers
ISSN
0007-0920
E-ISSN
1532-1827
DOI
10.1038/s41416-023-02298-8
